Magnesium cation

Identification

Name
Magnesium cation
Accession Number
DB01378
Description

Magnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.

Type
Small Molecule
Groups
Approved, Nutraceutical
Structure
Thumb
Weight
Average: 24.305
Monoisotopic: 23.985041898
Chemical Formula
Mg
Synonyms
  • Magnesium ion
  • Magnesium, ion(Mg2+)

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Nucleotide Sugars MetabolismMetabolic
Oxidation of Branched-Chain Fatty AcidsMetabolic
Sphingolipid MetabolismMetabolic
GlycolysisMetabolic
Amino Sugar MetabolismMetabolic
Folate MetabolismMetabolic
Fructose and Mannose DegradationMetabolic
Riboflavin MetabolismMetabolic
Arachidonic Acid MetabolismMetabolic
Acetylsalicylic Acid Action PathwayDrug action
Ketorolac Action PathwayDrug action
Lovastatin Action PathwayDrug action
Bromfenac Action PathwayDrug action
Meloxicam Action PathwayDrug action
Mefenamic Acid Action PathwayDrug action
Cerivastatin Action PathwayDrug action
Oxaprozin Action PathwayDrug action
Naproxen Action PathwayDrug action
Phenylacetate MetabolismMetabolic
Adenylosuccinate Lyase DeficiencyDisease
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)Disease
Ethylmalonic EncephalopathyDisease
Glutaric Aciduria Type IDisease
PhenylketonuriaDisease
HypercholesterolemiaDisease
S-Adenosylhomocysteine (SAH) Hydrolase DeficiencyDisease
Xanthine Dehydrogenase Deficiency (Xanthinuria)Disease
Glycine N-Methyltransferase DeficiencyDisease
Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD Deficiency)Disease
Dimethylglycine Dehydrogenase DeficiencyDisease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Magnesium cation.
AclidiniumThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Magnesium cation is combined with Alloin.
AlmasilateThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Almasilate.
Aluminium phosphateThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aluminium phosphate.
Aluminum hydroxideThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aluminum hydroxide.
AmantadineThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Magnesium cation.
AmiodaroneThe therapeutic efficacy of Magnesium cation can be decreased when used in combination with Amiodarone.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
KALSIMAG-D3 EFERVESAN GRANUL ICEREN SASE, 30 ADETMagnesium cation (493.37 mg) + Calcium carbonate (2500 mg) + Cholecalciferol (880 IU)Granule, effervescentOralBERKO İLAÇ VE KİMYA SAN. A.Ş.2020-08-14Not applicableTurkey flag
KALSIMAG-D3 EFERVESAN GRANUL ICEREN SASE, 40 ADETMagnesium cation (493.37 mg) + Calcium carbonate (2500 mg) + Cholecalciferol (880 IU)Granule, effervescentOralBERKO İLAÇ VE KİMYA SAN. A.Ş.2020-08-14Not applicableTurkey flag
MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 10 ADETMagnesium cation (342 mg) + Magnesium carbonate (670 mg)GranuleOralBİLİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 20 ADETMagnesium cation (342 mg) + Magnesium carbonate (670 mg)GranuleOralBİLİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
MAGVEL 365 MG GRANÜL İÇEREN SAŞE, 30 ADETMagnesium cation (342 mg) + Magnesium carbonate (670 mg)GranuleOralBİLİM İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as homogeneous alkaline earth metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkaline earth metal atom.
Kingdom
Inorganic compounds
Super Class
Homogeneous metal compounds
Class
Homogeneous alkaline earth metal compounds
Sub Class
Not Available
Direct Parent
Homogeneous alkaline earth metal compounds
Alternative Parents
Not Available
Substituents
Homogeneous alkaline earth metal
Molecular Framework
Not Available
External Descriptors
monoatomic dication, divalent metal cation, magnesium cation (CHEBI:18420) / a cation (MG+2)

Chemical Identifiers

UNII
T6V3LHY838
CAS number
22537-22-0
InChI Key
JLVVSXFLKOJNIY-UHFFFAOYSA-N
InChI
InChI=1S/Mg/q+2
IUPAC Name
magnesium(2+) ion
SMILES
[Mg++]

References

Synthesis Reference

David S. Thompson, John S. Prestley, Jr., Thomas E. Webb, "Aluminum-magnesium alloys sheet exhibiting improved properties for forming and method aspects of producing such sheet." U.S. Patent US4151013, issued 0000.

US4151013
General References
Not Available
Human Metabolome Database
HMDB0000547
KEGG Compound
C00305
PubChem Compound
888
PubChem Substance
46508750
ChemSpider
865
BindingDB
15
RxNav
1426853
ChEBI
18420
Therapeutic Targets Database
DCL000876
PharmGKB
PA164712884
PDBe Ligand
MG
Wikipedia
Magnesium
AHFS Codes
  • 88:29.00* — Minerals
  • 88:28.00 — Multivitamin Preparations
PDB Entries
101d / 109d / 119d / 121p / 13pk / 146d / 150d / 159d / 184d / 1a05
show 17406 more
MSDS
Download (73.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • American Regent
  • American Therapeutics Medicines Inc.
  • Bioniche Pharma
  • Claris Lifesciences Inc.
  • DSM Corp.
  • Luitpold Pharmaceuticals Inc.
  • Mallinckrodt Baker Inc.
  • McGuff Co. Inc.
  • Merit Pharmaceuticals
  • Pekana Naturheilmittel GmbH
  • Torrance Co.
  • United Guardian Inc.
Dosage Forms
FormRouteStrength
Tablet, effervescent
Granule, effervescentOral
Tablet
GranuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)651 °CPhysProp
boiling point (°C)1100 °CPhysProp
Predicted Properties
PropertyValueSource
logP-0.57ChemAxon
pKa (Strongest Acidic)3.09ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8382
Blood Brain Barrier+0.9708
Caco-2 permeable+0.7056
P-glycoprotein substrateNon-substrate0.8831
P-glycoprotein inhibitor INon-inhibitor0.9869
P-glycoprotein inhibitor IINon-inhibitor0.9855
Renal organic cation transporterNon-inhibitor0.9176
CYP450 2C9 substrateNon-substrate0.8465
CYP450 2D6 substrateNon-substrate0.823
CYP450 3A4 substrateNon-substrate0.8094
CYP450 1A2 substrateNon-inhibitor0.8824
CYP450 2C9 inhibitorNon-inhibitor0.9221
CYP450 2D6 inhibitorNon-inhibitor0.9555
CYP450 2C19 inhibitorNon-inhibitor0.9469
CYP450 3A4 inhibitorNon-inhibitor0.9846
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9015
Ames testNon AMES toxic0.9663
CarcinogenicityCarcinogens 0.6381
BiodegradationReady biodegradable0.9031
Rat acute toxicity2.0881 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Buchachenko AL, Kuznetsov DA, Berdinskii VL: [New mechanisms of biological effects of electromagnetic fields]. Biofizika. 2006 May-Jun;51(3):545-52. [PubMed:16808357]
  2. Sirijovski N, Olsson U, Lundqvist J, Al-Karadaghi S, Willows RD, Hansson M: ATPase activity associated with the magnesium chelatase H-subunit of the chlorophyll biosynthetic pathway is an artefact. Biochem J. 2006 Dec 15;400(3):477-84. [PubMed:16928192]
  3. Balasubramaniyan V, Nalini N: Leptin alters brain adenosine triphosphatase activity in ethanol-mediated neurotoxicity in mice. Singapore Med J. 2006 Oct;47(10):864-8. [PubMed:16990961]
  4. Nogovitsina OR, Levitina EV: Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Behav Physiol. 2007 Mar;37(3):199-202. [PubMed:17294093]

Drug created on July 06, 2007 20:30 / Updated on April 20, 2021 12:57